abstract |
There have been required drugs for treating diseases in the progress of which IGF participates, for example, cancer, acromegaly and diabetic complications. It is intended to provide a recombinant antibody capable of binding specifically to human IGF-I and human IGF-II and inhibiting the biological activities of human IGF-I and human IGF-II, or a fragment of this antibody; a transformant producing the above antibody or a fragment thereof; a process for producing the above antibody or a fragment thereof; and a drug containing the above antibody or a fragment thereof as the active ingredient. |